Stryker Corporation (SYK)

In our clinic, the integration of advanced robotics and platforms like the Mako system remains central to procedural volume growth, though we are monitoring how quickly ambulatory surgery center adoption picks up given current workflow and capital allocation realities. When evaluating orthopedic device pipelines, our surgical teams focus heavily on the reliability of operating room equipment and seamless procedural execution, especially as technology ecosystems become more complex and vulnerable to unforeseen network disruptions.

On our desk, SYK is viewed as a high-quality MedTech compounder that easily shook off the temporary Q1 cyber incident noise. With Q2 revenue hitting $6.59 billion and EPS beating consensus at $3.69, management's decision to reaffirm full-year organic growth guidance between 8% and 9.5% has reinforced our bullish thesis. Even though insider selling over the past 90 days has crossed $100 million, institutional accumulation via 13F filings shows strong conviction ahead of the back half of 2026.

Watching the valuation metrics closely, Simply Wall St's fair ratio flags Stryker as overvalued at a 35.9x P/E compared to a 30.9x benchmark. While the fundamental demand drivers in reconstructive orthopedic implants and peripheral vascular portfolios—bolstered by the Amplitude Vascular Systems acquisition—are intact, macroeconomic headwinds including hospital capex sensitivities to interest rates and potential Chinese import tariffs present non-trivial baseline risks for margin expansion.